Side effects include:
Oral or parenteral therapy: Headache, sometimes severe.

IM therapy: Transient pain at injection site.

IV therapy: Transient local burning or itching.

The most commonly reported side effect for IM administration was injection site pain, and the most commonly reported side effects with IV administration were localized pain and burning.
Uncommon ( to ): Abdominal discomfort/pain, constipation, nausea, vomitingVery rare (less than ): Acute pancreatitis, diarrhea
Abdominal pain, constipation, and nausea tended to improve with continued treatment.
Rare ( to ): Hypotension, chest pain, arrhythmia, bradycardia, atrioventricular block, tachycardia, premature ventricular beatsVery rare (less than ): Asystole, vasculitis
Bradycardia, atrioventricular block, tachycardia, and asystole have occurred in H receptor antagonists.
Rare ( to ): Insomnia, reversible mental confusion, agitation, depression, hallucinationsFrequency not reported: Loss of libido
Headache may be related to administration of treatment.
Rare ( to ): Dizziness, somnolence, vertigo, reversible involuntary movement disordersVery rare (less than ): Headache/severe headache
Rare ( to ): Urticaria, angioneurotic edema, skin rashVery rare (less than ): Erythema multiforme, alopecia
Very rare (less than ): Musculoskeletal symptoms, arthralgia, myalgia
Rare ( to ): Transient and reversible changes in liver function tests, increased ALT levelsVery rare (less than ): Hepatocellular/hepatocanalicular/mixed hepatitis with/without jaundice
Hepatitis with/without jaundice were usually reversible.
ALT levels increased to at least  times the pretreatment levels in patients receiving high IV doses for at least  days.
Rare ( to ): Fever, malaiseFrequency not reported: Death
Rare ( to ): Hypersensitivity reactionsVery rare (less than ): Anaphylactic shock/anaphylaxis
Anaphylactic shock occurred after administration of a single dose.
Rare ( to ): Elevation in serum creatinineVery rare (less than ): Acute interstitial nephritis
Elevation in serum creatinine was usually slight, and typically normalized with continued treatment.
Rare ( to ): BronchospasmFrequency not reported: Dyspnea, pneumonia
Rare ( to ): Reversible blurred vision
Very rare (less than ): Blood count changes, leukopenia, thrombocytopenia, granulocytopenia, agranulocytosis, pancytopenia, marrow hypoplasia/aplasiaFrequency not reported: Aplastic anemia, immune hemolytic anemia/acquired immune hemolytic anemia, eosinophilia
Leukopenia, granulocytopenia, and thrombocytopenia were usually reversible.
Very rare (less than ): Reversible impotence, breast symptoms/conditions, galactorrhea
Very rare (less than ): Gynecomastia
Postmarketing reports: Acute porphyria
Frequency not reported: Injection site pain, transient localized burning or itching